Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Mesoblast ADR Representing 10 Ord Shs MESO

Healthcare Biotechnology
Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:MESO)

Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2024

GlobeNewswire October 30, 2024

Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product Launch

GlobeNewswire September 29, 2024

Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2024

GlobeNewswire August 28, 2024

Mesoblast Financial Results and Corporate Update Webcast

GlobeNewswire August 27, 2024

Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2024

GlobeNewswire July 30, 2024

FDA Accepts Mesoblast's Biologics License Application (BLA) for Ryoncil® in Children With Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)

GlobeNewswire July 23, 2024

Patient Enrollment Commenced in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain

GlobeNewswire July 21, 2024

Mesoblast Resubmits Biologics License Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil® in Children with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)

GlobeNewswire July 8, 2024

Mesoblast to File Biologics License Application for Ryoncil® FDA Approval Next Week

GlobeNewswire July 1, 2024
View More News ››

Opinion & Analysis (NDAQ:MESO)

Biotech to Test Stem Cell Product in COVID-19-Caused Acute Respiratory Distress

Streetwise Reports May 14, 2020

Mesoblast Shares Soar 120% After Reporting 83% Survival Rate in COVID-19 Patients with ARDS

Streetwise Reports April 27, 2020

Biotech to Test Stem Cell Product in COVID-19-Caused Acute Respiratory Distress

Streetwise Reports April 16, 2020

'Stay Tuned for Data' from Regenerative Medicine Firm with 'Blockbuster Opportunity'

Streetwise Reports February 3, 2020

Fiscal Year 'Reads Well' for Regenerative Medicine Company

Streetwise Reports September 5, 2019

Australian Regenerative Medicine Firm 'Lands a Great Partner in China'

Streetwise Reports July 23, 2018
View More Opinion ››

Bullboard Posts (NDAQ:MESO)

Learn to Evaluate (MESO) using the Charts

News; $MESO Learn to Evaluate (MESO) using the Charts2024-06-17 04:20:00 ET Stock Traders Daily has produced this trading report using a...
whytestocks - June 17, 2024

KGC, IAU, NEM, GFI, MESO showing five-day upward surge

BREAKING NEWS: $MESO KGC, IAU, NEM, GFI, MESO showing five-day upward surge2024-04-02 10:45:02 ET Kinross Gold Corp. (KGC) KGC is...
whytestocks - April 2, 2024

$iMIN making moves in Ethereum Crypto !! 🚀🚀🚀🚀🚀

iMining Launches Fractional Staking to Enable Retail Investors to Participate in Ethereum 2.0's Proof-Of-Stake Mining Vancouver...
Saaaa1 - May 6, 2021

Mesoblast

Awaitng FDA approval  Sept 30. Very exciting times. This is a paradigm changing medical treatment. If approved looking for extension...
Tennis58 - September 29, 2020
View more Bullboard ››

Indiva Ltd

Indiva Ltd

Indiva Limited, through its indirect wholly owned subsidiary, Indiva Inc., is a Canada-based producer of cannabis servicing ...
View More »